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Abstract: Myxomatous mitral valve disease is the single most important mitral valve disease in both
dogs and humans. In the case of the dog it is ubiquitous, such that all aged dogs will have some
evidence of the disease, and for humans it is known as Barlow’s disease and affects up to 3% of
the population, with an expected increase in prevalence as the population ages. Disease in the two
species show many similarities and while both have the classic myxomatous degeneration only in
humans is there extensive fibrosis. This dual pathology of the human disease markedly affects the
valve transcriptome and the difference between the dog and human is dominated by changes in
genes associated with fibrosis. This review will briefly examine the comparative valve pathology and
then, in more detail, the transcriptomic profiling and gene expression reported so far for both species.
Keywords: canine; human; myxomatous mitral valve disease; Barlow’s disease; transcriptomic
profiling
1. Introduction
Myxomatous mitral valve disease (MMVD) is the most important acquired cardiac disease of the
dog, with almost all dogs developing some form of the disease if they live long enough [1]. MMVD
is also described in humans with 2%–3% of the global population estimated to have the disease
and approximately 15% of those affected requiring valve surgery [2–4]. The disease has previously
been reported to share many similarities between the two species, with the dog suggested as a
potential model for the human disease [1,5,6]. However there are important differences in pathological
appearance and these differences are also evident in the gene changes found with transcriptomic
profiling [2,7–10]. This review will examine the similarities and differences between MMVD in the dog
and human, with a particular emphasis on the gene changes identified on transcriptomic profiling and
real time polymerase chain reaction (RT-PCR). To date there is one study using RNA sequencing in the
dog and none for human MMVD [11].
2. Comparative Pathology
When comparing canine and human MMVD it is the difference in pathology that is the most
striking. The normal mitral valve in both species is reported to be relatively similar in structure [5].
Briefly, the valve consists of an outer layer of valvular endothelial cells (VECs) which are anchored
to the internal valve structure by a basement membrane consisting of proteins such as the laminins
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(LAMA1-5), the nidogens (NID1 & 2), type IV collagens and basement membrane-specific heparan
sulfate proteoglycan [12]. Towards the interior of the valve on the atrial side there is a highly organised,
but thin, layer of elastin fibres and mature collagen forming the atrialis, and this layer has been shown
to support valve movement through extension and recoil [13]. Beneath the atrialis is the spongiosa
which contributes to the valve structure and compressibility and primarily consists of a mixture of
proteoglycans (large and small) and glycosaminoglycans (GAGs) (in particular hyaluronan) which
covalently attach to proteoglycans, some free collagen fibres and valvular interstitial cells (VICs),
which express extracellular matrix components (ECM) [13,14]. Valvular interstitial cells (VICs) in
normal valves are for the most part quiescent so only operate in a homeostatic role [14–16]. Towards
the ventricular side of the valve is the fibrosa layer which is made up of densely packed collagen
fibres (types I, III and V mainly) with an intermingling of some elastin closer to the outer endothelial
layer (separately sometimes termed the ventricularis). The fibrosa and ventricularis together have a
more tensile role, protecting against prolapse from the strong hemodynamic forces during ventricular
ejection [13].
When the disease appears (which has a close association with age) and then progresses, there
are some similarities between dogs and humans. Myxomatous degeneration is typified by a
disorganization and dysregulation of the extracellular matrix of the valve, with expansion of the
spongiosa and loss of the fibrosa, dysfunction and potential loss of some of the VECs, and activation of
the VICs from a quiescent to an activated-myofibroblast phenotype [14,15,17–22]. It is activation of
the VICs which is thought to play a pivotal role in the development of disease through the release of
catabolic enzymes and the dysregulation of proteoglycan and collagen synthesis resulting in aberrant
remodelling [15,18,23]. In areas of myxomatous degeneration expansion of the spongiosa (containing
activated VICs) is observed with increased presence of GAGs, proteoglycans, disorganized collagen
fibrils as well as increased retention of water [14,21,23–26]. In both the atrialis and fibrosa there is also
a breakdown of the ordered collagen and elastin layers, and all this contributes to the eventual problem
of valvular incompetency [23]. Lastly, while MMVD can affect both leaflets in the dog, it mainly affects
the posterior leaflet in humans [6,27,28]. These changes are summarised in Figure 1.
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Figure 1. Schematic diagram summarising pathological changes seen in myxomatous degeneration. 
(A) Illustrates the normal valve structure and cellular composition. (B) Pathological changes 
associated with myxomatous disease; not shown is the development of fibrosis in the atrialis and 
fibrosa of the human valve. 
A clear contrast between human (Barlow’s Disease) and canine MMVD is the appearance of 
extensive fibrosis in the former [22,29,30]. Fibrosis of human valves occurs on both the atrial and 
ventricular surface and encases a central myxomatous core. The fibrosis forms so called “over-lays” 
on the atrial surface which tends to be more severely affected [22,30]. In addition, complicating the 
human picture is that several diseases including rheumatic fever, bacterial endocarditis and 
fibroelastic deficiency (FED) cause valve changes, and the term mitral valve prolapse (MVP) is often 
used without referencing the disease which caused the MVP. For these reasons clinical phenotype 
has to be carefully considered when evaluating for gene expression in human mitral valve disease. 
Figure 1. Schematic diagram summarising pathological changes seen in myxomatous degeneration.
(A) Illustrates the normal valve structure and cellular composition. (B) Pathological changes associated
with myxomatous disease; not shown is the development of fibrosis in the atrialis and fibrosa of the
human valve.
A clear contrast between human (Barlow’s Disease) and canine MMVD is the appearance of
extensive fibrosis in the former [22,29,30]. Fibrosis of human valves occurs on both the atrial and
ventricular surface and encases a central myxomatous core. The fibrosis forms so called “over-lays”
on the atrial surface which tends to be more severely affected [22,30]. In addition, complicating
the human picture is that several diseases including rheu atic fever, bacterial endocarditis and
fibroelastic deficiency (FED) cause valve c anges, and the term mitral valve prolapse (MVP) is often
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used without referencing the disease which caused the MVP. For these reasons clinical phenotype
has to be carefully considered when evaluating for gene expression in human mitral valve disease.
FED contrasts with Barlow’s disease in that it has relatively fast onset (months) and is the result of
deficiency in key connective tissue components including collagens, proteoglycans and elastin with
chordae rupture being a common occurrence, for this reason Barlow’s disease is more analogous with
canine MMVD [2,31,32]. Greenhouse and others [2] report the transcriptome for human MVP, but
define that as FED. Overall, the myxomatous changes appear to be similar in the dog and human, but
while studies have effectively evaluated the transcriptome of myxoid degeneration in the dog, this has
not been possible in human MMVD due to the preponderance of fibrosis [5,8,10,21,23,33]. There are
limited data on the cellular changes that might be involved in or contributing to the fibrotic response
in human valves.
3. Gene Changes in Canine and Human MMVD
There are limited amounts of data on the valve transcriptome and specific gene changes, as
assessed by RT-PCR, in both dogs and humans, but enough data to show consistent changes that
allow hypothesis driven studies examining putative signalling pathways contributing to disease
pathogenesis, and to identify those genes active in end-stage disease. There are marked differences in
gene expression between the species, but there are also certain caveats that need to be considered for
the studies reported to date. For the dog, identifying age-matched normal controls is nearly impossible
since all dogs have some evidence of the disease as they age. For human MMVD problems arise
with accurate phenotyping due to the heterogeneity of degenerative valvulopathies, and what tissue
is sampled is based on the patient’s clinical need. Not surprisingly, reports have been primarily
on advanced stage disease with limited data on changes as disease progresses in both species.
An additional confounding factor is that most patients (in both species) will likely have been on
cardiac medications, the effects of which on valve gene expression are currently unknown.
Transcriptomic profiling with bioinformatic analysis allows identification of gene signal intensity,
gene changes between groups, gene ontology enrichment, network identification, functional clustering
and biological effect annotation. This can give powerful insight into gene function in disease, but needs
to be interpreted with some caution. Proof that genes are actually expressed requires RT-PCR validation
and that in itself does not confirm that there is protein translation. Nevertheless, transcriptomic
profiling indicates relevant signalling pathways that can be then interrogated in greater detail and
functionally assessed.
Varying numbers of genes have been identified to be differentially expressed in both the dog
and human and the numbers reported depend on finalized intensity cut-off using fold change
(typically > 1.5) and false discovery rate (FDR < 0.05) [2,7–10,34]. For the reports by Thalji and
others (human) and Lu and others (canine) 2602 and 5397 differentially expressed genes were found
respectively using the same FDR and fold change [8,10]. With further filtering based on signal intensity,
but not reported for the human transcriptome, Lu and others reduced the number to 591 differentially
expressed annotated canine genes [8]. Comparison between these two studies is shown in Tables S1
and S2. In the single study that used high-throughput RNA sequencing in the dog, 263 genes were
found to be differentially expressed [11].
While differential expression is clearly important in any gene study, the intrinsic gene expression
can also be of interest (as assessed by signal intensity), but is rarely reported, and within certain families
of genes there can be high signal intensity genes indicting their importance in tissue homeostatic
control. Examples for the dog include genes important in tissue structure such as collagen genes COL
1A1, 2 & 3, 12A1 and 14A1 as well as the proteoglycans lumican (LUM) and versican (VCAN). Further
exemplifying this point is the high expression of the matrix-metalloproteinases (MMP) MMP2, 14 and
19 and their tissue inhibitors (TIMP) TIMP2 and 3 which are required for control of the ECM, and there
are many more examples [8].
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For MMVD, dogs and humans do share gene changes based on gene ontology and KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway analysis. For example, ECM, cell signalling,
cell movement, cardiovascular development, inflammation and endothelial-to-mesenchymal transition
(EndoMT), but with some variation between studies [2,7–11,34]. Many of these functional changes are
not surprising considering the pathology of MMVD, not least affecting the ECM, but others such as
inflammation likely represent signalling pathways involved in a whole range of biological functions.
In the canine MMVD transcriptome there is consistent increased expression of inflammatory
genes, but this is not consistently reported in human MMVD [2,7–9,11,34]. There is a small increase in
macrophage and mast cell number in canine MMVD, which is not seen in human valves, but is located
towards the valve base and not in areas affected by disease [6,16,35,36]. In the inflammation category
the main gene changes are in the expression of toll-like receptors and interleukins, which are involved
in both the control of inflammation as well as other biological pathways. Changes in these two gene
families are observed in both human and canine profile sets but do not, in many cases, show matching
changes in specific genes [8,10]. This may be indicative of differences in the phenotypic changes in the
VIC and VEC populations in both disease [37]. However, a better understanding of the phenotypic
switch of VICs, as well as the potential role of EndoMT in VECs, is required before any conclusions
can be drawn.
Endothelial-to-mesenchymal transition (EndoMT) occurs in canine MMVD, and in induced ovine
models of the disease, with increased co-expression of the myofibroblast marker alpha-smooth muscle
actin; α-SMA (encoded by the ACTA2 gene) and the endothelial cell marker platelet endothelial
cell adhesion molecule 1; CD31 (PECAM1) in endothelial cells that have migrated into the valve
stroma [38,39]. It is hypothesized that this also occurs in human MMVD, but has yet to be confirmed.
Comparing the transcriptomic data for both species suggests EndoMT does occur in humans MMVD.
There is decreased gene expression for the key basement membrane components NID1 and LAMA2
in both species and decreased gene expression of COLI4A1, A2 and A6 in humans, all of which
will allow for greater migratory potential of endothelial cells [8,10]. This is reflected in a loss of
endothelial cells in humans similar to that seen in dogs during the disease [17,36]. Additionally,
downregulation of the cell-cell adhesion glycoprotein vascular endothelial cadherin gene (CDH5) and
increased expression of the pro-migratory protein hyaluronic synthase 2 (HAS2) [8,10,34], required
for EndoMT, has been shown in both species, and confirmed by immunohistochemistry (IHC) in the
dog [38]. The mechanisms underpinning activation of EndoMT have yet to be identified, but NOTCH
signalling appears not to be involved in the dog [38].
There are additional endothelial-related gene changes that are different between the two
species. Canonical pathways involved in endothelial function are activated in the dog, including
endothelin-1 signalling, but several endothelium-related genes are typically downregulation in human
MMVD [10,38]. Increased nitric oxide synthase expression is found in canine MMVD and is important
in regulating oxidative stress, and reactive oxygen species are changed in human MMVD [11,40].
However, while the role of endothelial damage and dysfunction is well recognised in the dog, this has
not yet been comprehensively reported in human MMVD [19,20,41,42].
Not surprisingly ECM gene changes are important features of the disease transcriptome
in both species. Despite the well characterised pathological changes observed in MMVD,
the precise underlying molecular mechanisms responsible for disease development remain
unknown [15,16,18,29,43]. ECM remodelling is presumed to be due to phenotypic transition
of quiescent VICs into an activated myofibroblast phenotype. This change in phenotype can,
as previously mentioned, be measured by increased expression of α-SMA, identified by IHC and
RT-PCR [15,16,18,44]. Paradoxically, to date increased α-SMA mRNA expression has not been shown
by transcriptomic profiling in either canine or human MMVD [9–11,34,38,45]. Regardless of this,
activation of VICs to a myofibroblastic phenotype is thought to be critical to disease development and
understanding the cause of this activation is of major research interest.
Vet. Sci. 2017, 4, 34 5 of 13
Several gene families and signalling pathways have been implicated not only in this VIC activation
process, but also in other aspects of disease including EndoMT, metalloprotease production and
dysregulation of ECM protein synthesis [2,7,8,10,40,45–47]. Of particular interest are the transforming
growth factor-β (TGF-β), the renin-angiotensin and serotonergic signalling pathways. Disease links
to these have been identified both through focused histopathological and gene studies as well
as transcriptome wide analysis. As previously mentioned, comparison between dog and human
is complicated by the fibrotic component of human MMVD, such that the human transcriptome
is dominated by the TGF-β signalling pathway, presumably driving fibrosis through canonical
Suppressor of mothers against decapentaplegic (SMAD) signalling [40].
The TGF-β superfamily itself contains many structurally similar proteins including the TGF-β
subfamily (TGF-β1-3) and the bone morphogenetic proteins (BMPs) [7,48]. BMPs, particularly BMP2
and 4, play a role in development of the valve cusp [49,50]. Their importance in valve development
implicates them in disease as they regulate many of the changes seen such as ECM modification and
EndoMT activation. BMP4 is upregulated, alongside the downstream signalling components Cartilage
oligomeric matrix protein (COMP) and SOX9, in human MMVD valves [34]. In the dog BMP6 is
consistently upregulated [8,9]. The BMPs function through SMAD and non-SMAD (extracellular
regulated protein kinases (ERK) 1/2 etc.) pathways to elicit transcriptional and non-transcription
effects that modify cell actin organization, and cell migration, survival and differentiation, which are
all cardinal features of MMVD [15,16,18,20,40,49–51].
With respect to TGF-β1 and 2 signalling there are distinct differences currently reported comparing
canine and human MMVD. The TGF-β signalling pathway has a major role in myofibroblast
differentiation, EndoMT and alteration in ECM protein and MMP activity in myocardial disease
and cardiac fibrosis [52,53]. In dogs, currently no significant changes in gene expression assessed by
transcriptomic profiling of the TGF-β superfamily have been identified, except in the expression of ENG
(endoglin, part of the TGF-β receptor complex) and BMP6 mentioned above [8,9,11]. This contrasts
with protein and gene expression measured by IHC and RT-PCR showing variably increased expression
of TGF-β1, 2 and 3 and TGF-β2 receptor in diseased canine valves [46,54,55]. Furthermore, assessment
of canine VICs in culture has shown that exogenous TGF-β1 can cause myofibroblast differentiation, as
in human VICs, suggesting a role in disease [56,57]. Contrasting to the dog, transcriptomic findings for
TGF-β family members in human valves seem to be more consistent. There is a consistent upregulation
in TGF-β2 and it is widely thought that this upregulation causes the remodelling seen in human
MMVD [2,7,10,34,45]. Local increase in the expression of TGF-β1, using RT-qPCR, has also been
reported [40]. These findings in human valves are expected, considering the fibrotic component of the
disease. The downstream signalling changes, including increased expression of MMP2, connective
tissue growth factor (CTGF), and the SMAD-specific ligases SMURF1 and 2, as well as increased
phosphorylated SMAD2/3, further support the idea that TGF-β1 canonical pathway signalling drives
fibrosis in human MMVD, with an associated increase in collagen types I and III [40,58]. At present it
is problematic to explain the role of TGF-β in canine MMVD, except for the decreased expression of
ENG which can dampen the pro-fibrotic effects of TGF-β, and further work is need in this area [8].
There is, however, consistently reported increased expression of the 5-HT (5-hydroxytryptamine
or serotonin) receptor genes 5HTR2B in dog and 5HTR2A in human MMVD, as well as an increase
in the serotonergic pathway rate limiting enzyme tryptophan hydroxylase 1 (TPH1) in human and
dog mitral valves, and an increase in TPH1 gene expression in canine MMVD [8–10,59]. Serotonergic
signaling has been associated with a range of valvulopathies and can affect TGF-β signalling. 5HT can
induce VIC proliferation and ECM production through the activation of ERK1/2 pathways, but has
not been shown to increase α-SMA expression in the same cells [60,61]. Likewise angiotensin 2 (AGT2)
has been associated with disease, via renin-angiotensin signalling, through its known role in cardiac
remodelling hypertrophy and induction of some aspects of MMVD in a mouse model [10,62]. Inhibiting
AGT2 signalling not only improves MMVD outcomes in dogs, but also attenuates TGF-β signalling
in human VICs [63,64]. However, no direct changes in protein or gene expression of members of the
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angiotensin family have been found in MMVD in either species. Interestingly, interactions between the
AGT2 type 1 receptor (AT1) and 5HTR2B receptor have previously been suggested, and combined
stimulation with 5HT and AGT2 in both a mouse model of MMVD and porcine cultured VICs induces
valve remodelling and increases expression of α-SMA [65,66]. It may be that MMVD requires similar
co-regulation by different factors in order to progress MMVD and initiate ECM dysregulation.
Important in the control of ECM production and homeostasis are the MMP and ADAMTS
(A Disintegrin and Metalloprotease with Thrombospondin Motifs) metalloproteases and their
inhibitors TIMPs. MMP and TIMP protein and gene expression in diseased valves have been reported,
but the findings are inconsistent [6,8,9,11,15,67]. The inconsistency in valve expression may reflect
remodelling activity at the time of sampling as MMPs (and therefore TIMP expression) can be transient,
but MMPs likely have some role in valve remodelling in disease [68]. Further contrasts between species
have been reported with the elastin degrading proteases MMP2 and 9, showing increased protein
expression and activity in humans [69], but no change in MMP9 and reduced MMP2 in diseased canine
valves [70]. Interestingly an increase in mRNA for a different elastin degrading protease MMP12 has
been found in the dog transcriptome [8], but not in human. There are significant decreases in MMP14
and 16 expression in the dog, both important in degradation of several ECM components, but increased
expression of MMP16 in human valves [8,10,68]. The ADAMTS family of genes, like the MMPs, have
a wide variety of effects on the ECM through the cleavage of substrates and have been shown to be
affected in disease of both species. In human MMVD there is downregulation of ADAMTS1, 5 and
9 [10]. These proteases are involved in the cleavage of the proteoglycans aggrecan and versican, as well
as some other ECM components, and knockout and haplo-insufficient mouse models of ADAMTS5
and 9, respectively, have shown a MMVD phenotype [10,71–73]. Increased proteoglycan deposition
with MMVD is seen in both species. There is increased gene expression for versican in human
MMVD and downregulation of ADAMTS1, 5 and 9 which would contribute to increased versican
deposition [1,10,26,34,74]. In human valves there is upregulation of ADAMTS6 which currently has no
known substrate [10]. In the dog, there is significant downregulation of ADAMTS2, 19 and L4, with
ADAMTS2 and L4 having roles in procollagen maturation and fibrillin-1 binding respectively, whereas
the function of ADAMTS19 is currently unknown [8,71,75]. Reduced collagen turnover is recognised
in diseased canine valves and the downregulation in ADAMTS2 may be responsible for this [19,24,76].
For the small leucine-rich proteoglycans (SLRP) many members show high intensity gene expression
in canine mitral valves, but only chondroadherin (CHAD) and keratocan (KERA) have so far been
shown to be significantly downregulated, while HAPLN1 (hyaluronan and proteoglycan link protein 1)
is upregulated in human and downregulated in canine diseased valves [8,10,34,77]. In human MMVD,
in contrast to the dog, there is a tendency for increased SLRP protein expression, including decorin,
biglycan (and the proteoglycan versican mentioned above) [26,78]. Proteoglycans are fundamentally
important in the synthesis and organization of the spongiosa and fibrosa, derangement of both which
are cardinal features of MMVD.
There are many additional gene changes in MMVD that encompass a wide variety of
biological functions that would be too extensive to review here in detail. Examples include, genes
associated with oxidative stress, ossification, epithelial (endothelial) proliferation and potential
up-stream regulators such as interleukins, interferons, tumor necrosis factor (TNF), nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB), low density lipoprotein receptor (LDLR), and
the heat shock proteins (HSP). There is some evidence for the role of reactive oxygen species (ROS) in
human MMVD, with increased expression of nicotinamide adenine dinucleotide phosphate-oxidase
(NOX) 2 and 4, and this has also been identified in cultured valve cells from superoxide dismutase
(SOD1) knockout mice where there is upregulation of pro-fibrotic ROS associated genes [40]. Marked
downregulation of several members of the metallothionein family of genes in human valves, which
contrasts with reports of upregulation in the dog [9,11], is further evidence of oxidative stress in human
MMVD [10].
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Lastly, there is limited data on the differential expression of non-coding RNAs (ncRNAs) in valve
tissue. NcRNAs are fundamentally important in controlling gene expression. MicroRNAs, a class
of ncRNAs, act to maintain intracellular homeostasis and essentially “buffer” against rapid changes
in gene expression and cell metabolism. Their dysregulation is believed to have a fundamental role
in disease pathogenesis. Differential expression of microRNAs (miRs) has been reported in humans
comparing MMVD and FED [79], and changes in expression of 29 canine (pre-) miRs were mentioned
in one transcriptomic study [8]. In the dog there is evidence for a range of differentially expressed
miRs, all downregulated, but some with very low signal intensity requiring cautious interpretation
(C.C. Lu, pers.comm). Some miRs have high signal intensity indicating robust epigenetic control of
genomic expression in normal valves. One of the most striking changes is downregulation of miR-29,
which has extensive regulatory functions controlling ECM genes. Additional altered miRs in the canine
valve include 218, Let7c, 214, 30 and 15, which have varied effects on regulation of genes associated
with ECM, cell migration, differentiation and EndoMT. In human MMVD miR changes have been
reported when compared to FED, which is dominated by elastin fibre infiltration, but not to normal
valves. There were 20 miRs significantly differentially expressed between the two diseases. Target
prediction software identified various ECM genes regulated by the differentially expressed miRs and
differences in those ECM genes were found for several SLRPs [79]. Much further work is needed on
the role of miRs and other non-coding RNAs in canine and human MMVD.
4. Conclusions
To date there are a limited number of transcriptomic profiling studies for canine and human
MMVD, often with low sample numbers, making the drawing of categorical conclusions problematic.
More data, as well as data from a wider range of stages of disease, are needed to increase interpretative
confidence and to understand disease pathogenesis in full. Nevertheless, the current data gives
an insight into the signalling pathways involved in the MMVD, and so allows for more focused
hypothesis and mechanism-driven studies examining function. Furthermore, although there is a
similar gross pathology, and some of those similarities are carried through to molecular differences,
the transcriptomic data clearly show differences between canine and human MMVD that reflect the
contribution of fibrosis to end-stage disease pathology in humans. Additional studies will be needed
to examine local tissue gene expression and protein translation, to address why dogs do not develop
fibrosis and humans do, and hence the validity of the dog disease as a model of human MMVD.
Supplementary Materials: The following are available online at www.mdpi.com/2306-7381/4/3/34/s1, Table S1,
Partial comparison of gene fold changes in human MMVD (Thalji et al. 2015 [10]; 2602 differentially expressed
genes) with the 591 genes reported in the dog by Lu et al. 2015 [8]. Both studies used the same FDR and fold
settings, but Lu et al. also use signal intensity to derive a much smaller gene set from an original set of 5397
(not compared) differentially expressed genes. Only 83 differentially expressed genes were reported in both
data sets of which 40 showed the same direction of fold change (+ or −) and 43 had the opposite fold change.
The data illustrates that while there are similarities, there are also clear difference between human and canine
MMVD at the transcriptomic level. The full gene names are shown, Table S2. Some illustrative examples of
fold change for a selection of genes in human and canine MMVD, illustrating similar and dissimilar changes in
both species. 0 = no report of gene change. The genes selected represent signalling pathways involved in cell
differentiation, endothelial-to-mesenchymal transition, extra-cellular matrix and inflammation. Of particular note
are the differences in genes associated with myofibroblast activation.
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Abbreviations
MMVD Myxomatous mitral valve disease
RT-PCR Real time polymerase chain reaction
VEC Valvular endothelial cell
LAMA Laminin
NID Nidogen
GAG Glycosaminoglycan
VIC Valvular interstitial cell
ECM Extracellular matrix
FED Fibroelastic deficiency
MVP Mitral valve prolapse
FDR False discovery rate
COL Collagen
LUM Lumican
VCAN Versican
MMP Matrix-metalloproteinase
TIMP Tissue inhibitor of metalloproteinase
KEGG Kyoto Encyclopedia of Genes and Genomes
EndoMT Endothelial-to-mesenchymal transition
α-SMA Alpha-smooth muscle actin
CD31 Platelet endothelial cell adhesion molecule 1
CDH5 Vascular endothelial cadherin
HAS2 Hyaluronic synthase 2
IHC Immunohistochemistry
TGF-β Transforming growth factor–β
SMAD Suppressor of mothers against decapentaplegic
BMP Bone morphogenetic proteins
COMP Cartilage oligomeric matrix protein
ENG Endoglin
TGFBI TGF-β-induced
CTGF Connective tissue growth factor
5-HT 5-hydroxytryptamine
TPH1 Tryptophan hydroxylase 1
AGT2 Angiotensin 2
AT1 AGT2 type 1 receptor
ADAMTS A Disintegrin And Metalloproteinase with Thrombospondin Motifs
SLRP Small leucine-rich proteoglycans
CHAD Chondroadherin
KERA Keratocan
HAPLN1 Hyaluronan and proteoglycan link protein 1
TNF-α Tumor necrosis factor α
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells
LDLR Lipoprotein receptor
HSP Heat shock proteins
ROS Reactive oxygen species
NOX Nicotinamide adenine dinucleotide phosphate-oxidase
SOD Superoxide dismutase
ncRNAs Non-coding RNAs
miRs MicroRNAs
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